The FDA is publishing the letters that say why drugs get rejected — and the industry is fighting it

Biotech & Longevity 5 min 9 sources

For years a drug rejection was a private letter only the company saw. Now the FDA is posting them, and pharma has filed to stop it. Plus ADCs come for chemo, an Ebola trial races the outbreak, and a heart drug fails.

Key takeaways

The FDA is now publishing the letters that explain why it rejects drugs, and the industry has filed a formal petition to stop it — a fight over how much the public gets to see behind a company's own announcement.
Targeted cancer drugs called ADCs posted two more wins against standard chemotherapy in lung cancer, though both trials ran in China and full survival numbers are still unreleased.
In the DRC's Ebola outbreak — 625 dead, no approved drug or vaccine for this viral species — a treatment trial and a vaccine trial were both stood up in record time, racing the epidemic in real time.

When the US drug regulator turns down a new medicine, it sends the company a letter — a “complete response letter,” or CRL — spelling out exactly what went wrong: a safety signal, a trial too small, a factory that failed inspection. For most of the FDA’s history, only the company saw that letter. This year the agency started posting them for anyone to read, and the fight over whether it should is the biggest biotech story of the week.

The letters go public

The FDA (the US Food and Drug Administration, which decides whether drugs can be sold) released 14 more rejection letters on 10 July, days after it had quietly confirmed the disclosure policy was paused back in April [1]. Then it said the pause is over and more are coming: “FDA will continue to proactively publish appropriately redacted CRLs” [2]. The batch reached back to a rejected injectable form of nimodipine, a drug for bleeding around the brain, and included a liver-cancer combination from Hengrui and Elevar that has now been turned down three times [1].

Why this matters: a rejection has always been public in name. Companies are required to tell investors they got a CRL. But they were not required to share what it said — so they described it in their own words, often as a fixable “manufacturing item” rather than a failed safety test. Publishing the letter itself removes that gap between the vague announcement and the actual reason.

The industry is pushing back hard. An unnamed drugmaker filed a formal “citizen petition” against what it called the “radical transparency” policy, arguing the letters expose commercially sensitive information [2]. The disagreement is really about redaction — how much of each letter is blacked out before release. All of this lands while the FDA’s biologics centre, which oversees vaccines and cell therapies, is trying to steady itself under a new acting director after a turbulent stretch [3]. The caveat worth keeping: a released letter is a snapshot of one moment in a drug’s life. A “no” today is often a “not yet,” and the letter rarely tells the whole story of what happened next.

A quieter kind of cancer drug comes for chemotherapy

Two results this week pushed a class of cancer drugs called antibody-drug conjugates, or ADCs, further toward replacing standard chemotherapy. An ADC is a guided weapon: an antibody that homes in on a marker on tumour cells, carrying a toxic payload it drops off at the target — instead of chemo’s blast that also poisons healthy tissue.

GSK, working with China’s Hansoh Pharma, said its ADC ris-rez hit its main goal in a late-stage trial in small-cell lung cancer, extending survival compared with the standard chemotherapy [4]. Separately, Wall Street analysts called Merck’s ADC sac-TMT “direct proof-of-concept” that it could become part of front-line lung-cancer treatment [5]. Both are real signals that the targeted approach is maturing.

The caveats matter here. GSK announced its win in a press release and “didn’t provide specifics” — no survival numbers yet [4]. Both trials ran in China, and results still have to hold up across wider populations before regulators sign off. A hit on a trial’s main goal is a strong start, not an approval.

An Ebola trial races the outbreak

In the Democratic Republic of the Congo, an Ebola epidemic declared a public health emergency on 17 May has killed 625 people across 1,792 confirmed cases [6]. It is caused by the Bundibugyo species of the virus — and because Ebola’s six species are, in one scientist’s phrase, “sisters rather than twins,” there are no approved drugs or vaccines for this one [6].

So researchers are building the science while the fire burns. A treatment trial of two drugs enrolled its first patients in the Ituri region just six weeks after the emergency was declared — a record pace for standing up this kind of study [7]. In parallel, an Oxford team moved its new vaccine into a first human trial eight weeks after starting work, testing it for safety and immune response in 50 healthy adults aged 18 to 55 [6]. A phase 1 trial like this only checks whether the vaccine is safe and provokes the right immune reaction; it cannot yet show it stops the disease. The outbreak is in a conflict zone with a highly mobile population, and about 75% of known contacts are being traced [7].

A heart drug fails in the open

AstraZeneca and its partner Ionis said their drug Wainua failed a pivotal trial in ATTR-CM, a disease where a misfolded protein stiffens the heart muscle [8]. The drug did not beat a placebo at reducing cardiovascular death and hospital events. AstraZeneca’s shares fell around 8–9% and Ionis’s about 12% in early trading [8]. It is a clean example of the thing the new letters policy is about: a public failure, announced by the company, in a heart-disease field that has become fiercely crowded.

And a piece of ageing damage, reversed in a dish

The under-covered result this week comes from basic biology. As we age, our long-lived proteins accumulate a kind of chemical rust — “advanced glycation end products,” sugar-derived scars that have long been considered permanent [9]. Researchers engineered an enzyme, screening through more than 500 million variants, that specifically strips one of these scars off and restores the original protein — reversing damage previously deemed irreversible [9].

The honest limit: this was done in test tubes and in tissue samples from elderly donors, not in living people [9]. It is a proof-of-concept for a repair strategy, not a treatment. But it reframes a piece of ageing as something that might be undone rather than only slowed.

02 · Lesson · why it matters

A vague answer is a gift to whoever gives it

When one side holds the details, keeping the summary fuzzy isn't laziness — it's control, and the specifics are what take that control back.

Two sentences about the same event

A drug company gets turned down by the regulator. Here is how it tells the world: “We received a complete response letter and look forward to working with the agency to address its questions.” Calm. Procedural. The kind of line that makes an investor shrug and hold the stock.

Here is what the letter it received might actually say: the trial found a heart-rhythm risk, or the main measure of benefit came back no better than a sugar pill, or the factory failed inspection.

Same event. Two completely different meanings. The difference between them isn’t a lie. The company really did receive a letter, and it really is going to talk to the agency. The difference is everything the second version contains and the first one leaves out. For most of the FDA’s history, only the company ever saw the second version. This year the regulator started posting the actual letters — and the industry filed a formal petition to make it stop.

Vagueness is a resource, not an accident

When you know the details and the person across from you doesn’t, a fuzzy summary is worth something. It lets you decide what the event means before anyone else can check.

Notice this is not the same as lying. A lie can be caught against the facts. A compressed summary can’t, because the facts it would be checked against are the very thing it withholds. “We received a complete response letter” is true. It is also almost content-free. It answers the question — what happened with the FDA? — while handing you no way to judge the answer. That gap, between what happened and what you were told, is where the control lives. Whoever writes the summary gets to fill that gap with a frame of their choosing.

The reason the letters matter is not that they expose lies. It’s that they close the gap. Once the full reason is public, the company no longer owns the meaning of its own rejection.

You have been on the receiving end of this

This is not a quirk of drug regulation. It is one of the most common shapes in ordinary life, and you have stood on the thin end of it many times.

“We’ve decided to go in a different direction” — a rejection, stripped of the reason. “The company is restructuring” — you’re being let go. “It’s not you, it’s me.” “We faced some headwinds this quarter.” “Everything looks normal,” from a doctor who has seen the scan you haven’t. In each case one side holds the specifics and the other gets the label. And in each case you probably accepted the label, because you had nothing to weigh it against — the same position the investor is in when a press release says “complete response letter” and nothing more.

You are not a spectator watching pharma companies spin. You are a node in the same web, on the receiving end of a hundred compressed accounts you took on trust because the detailed version was never offered.

The privacy was a choice, and it had a beneficiary

It is tempting to treat “only the company saw the letter” as just the way things were. It wasn’t nature. It was a rule, and like every rule it had someone it served.

Kept private, a rejection stayed the company’s story to tell. That arrangement posed as neutral procedure — this is simply how the FDA operates — while quietly handing the advantage to the party with the information. Someone built it that way.

And here is the honest other half: the privacy also protected things worth protecting. A rejection letter can contain a rival’s trade secrets, or half-finished data that would be misread if dumped into the open. An arrangement can shield its maker’s interests and guard something real at the same time. The fight over the letters is not villains versus heroes. It is a fight over where to draw the line on redaction — how much detail the public gets before the company’s legitimate secrets begin. But watch who is fighting to keep the line tight, and you can see who the old shape was serving.

The tell is a summary you can’t check

Why does vagueness pass so easily? Because we treat a summary as if it were the thing it summarises. “We got a complete response letter” feels like information. It has a shape, a subject, an official ring. It is a label with the contents poured out.

The signal to watch for is simple: an answer that responds to your question while giving you no way to test it. “It’s being handled.” “There were performance issues.” “The results were mixed.” Each one is a door that looks open and is painted on a wall. Not every fuzzy answer is hiding something — sometimes the speaker doesn’t know more, or genuinely can’t say. But the fuzziness always does the same work regardless of intent: it leaves the meaning in the hands of whoever spoke.

What’s left when you see it

You cannot get the full letter for most things. That is the part that should sit uneasily. You will not read the real reason behind the layoff, the breakup, the quiet corporate “different direction.” The regulator publishing its letters is a rare case of a gap being closed on purpose, against the wishes of the people who benefited from it staying open.

The rest of the time, you are reading summaries — a headline, a statement, a manager’s word, a friend’s account of a fight — each one written by a person who chose what to keep in. Seeing that doesn’t mean assuming everyone is hiding something. It means holding a tidy explanation a little more loosely, and noticing whose hand shaped it, and how small a window any single account really is onto what actually happened.

03 · Lab · your turn

The Summary Desk

Hold the full reason, choose the public wording, and feel how a vague summary controls what others believe until the detail goes public.

04 · Hope · carry this

For decades the reasons behind a rejected drug stayed sealed, and this week a regulator chose to unseal them anyway. A gap that served the people holding it can still be pried open on purpose — daylight is a decision, not an accident.